ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0418

Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis

Patricia Vega-Fernandez1, Kelly Rogers2, Alyssa Sproles2, Sherry Thornton1, Lexi Auld3, Jackeline Rodriguez-Smith1, Ekemini Ogbu1, Kara Murphy Schmidt4, McKenzie Vater5, Katelyn Banschbach6, Grant Schulert1, Alexei Grom1, Sheila Angeles-Han2, Hermine Brunner1, Jennifer Huggins7, Daniel Lovell1, Amy Cassedy8, Yuriy Baglaenko2, Tracy Ting1 and Sara Szabo1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 4Cincinnati Children’s Hospital Medical Center, Louisville, KY, 5Cincinnati Children's Hospital Medical Center, Fort Thomas, KY, 6cincinnati Children's hospital, Villa Hills, KY, 7Cincinnati Children's Medical Center, Cincinnati, OH, 8Cincinnati Children's hospital medical center, cincinnati, OH

Meeting: ACR Convergence 2025

Keywords: Biomarkers, Imaging, Juvenile idiopathic arthritis, Pediatric rheumatology, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinical, radiologic and biomarker data are measurements used in the assessment of juvenile idiopathic arthritis (JIA) disease activity. The development of ultrasound-guided synovial biopsy (USGSB) in children has accelerated synovial histopathology research. Investigate the relationship between clinical features of arthritis, radiologic synovitis, synovial fluid (SF) biomarkers of inflammation, and histologically confirmed synovitis in children with JIA.

Methods: JIA patients requiring a knee joint injection were enrolled. Patients underwent standardized clinical assessment (cJADAS, range 0-30), a musculoskeletal ultrasound (MSUS) examination, and USGSB of the affected knee with collection of synovial fluid (SF). MSUS images were collected and scored by pediatric MSUS experts. MSUS synovitis was scored using a validated semiquantitative MSUS scoring system for the knee joint (MSUS-knee score, range 0-6). Synovial biopsy inflammation was determined by Krenn’s score (KS, which examines for synovial hyperplasia, stromal cellularity/reactivity and inflammatory infiltrate, range 0 to 9, higher scores indicating greater severity. Biomarkers measured in SF included: TNFR1, IL-6, IL-10, MCP-1, ANG-1, ANG-2, MMP-2, MMP-8, CCL18, CCL20, IFNg, IL-17a, IL-2Ra, IL-23, IL-18, resistin, CXCL9, VEGF, TIMP-1 by Luminex, and S100A12, S100A8/A9 by ELISA. Wilcoxon Rank Sum test was used to compare group differences. Spearman correlation (rs) was used to assess the relationship between the studiedvvariables

Results: Thirty-four patients [mean age 10 (SD 5.1)] were enrolled. Their median cJADAS score was 4 (IQR 2-8) while 32% of them had no pain at the affected joint (Table 1). All patients had presence of MSUS synovitis with a median MSUS-knee score of 5 (IQR 4-6). Median KS was 6 (IQR: 4-7). Children receiving conventional and/or biologic disease modifying medications (DMARDs) had similar median KS compared to children not on these treatments [6, (IQR 3-7) and 6 (IQR 5-8), respectively] (p=0.962). Children with polyarticular JIA had a median KS of 5 (IQR 5-6) while the KS for children with oligoarticular was 6 (IQR 4-8) (p=0.725). Children with oligoarticular JIA taking NSAIDs at the time of the USGSB had a significantly lower KS than oligoarticular JIA children not on an NSAID [median 3.5 (IQR 3-4) v 6.5 (IQR 4.2-7.7), respectively] (p=0.033). A significant moderate correlation was found between the MSUS-knee score and the KS rs: 0.45 (0.12 -0.7), with the highest association being between the KS stroma domain and the MSUS-knee score [rs: 0.5 (0.17-0.720] (Table 2). Strong significant correlations (rs>0.8, p< 0.05) were found between SF levels of S100A12, S100A8A9, CCL18, IL-6, MMP-8 and the KS (Table 3). S100A8A9 also had a significant correlation with the MSUS-knee score [rs 0.55 (0.08-0.82)].

Conclusion: This pilot study suggests that the degree of inflammation as measured by the KS does not associate with JIA disease category or DMARDs use but may be modified by concomitant NSAID use The association of the MSUS-knee score and SF biomarkers of inflammation with the KS detected in this study suggest that these measurements may have a role as surrogate markers of histologically confirmed active synovitis.

Supporting image 1Table 1. Clinical Characteristics of Patients Involved (n=34)

Supporting image 2Table 2. Relationship between MSUS-knee score and Krenn’s scores (n=34)

Supporting image 3Table 3. Relationship between Synovial Fluid Biomarkers and Krenn’s scores (n=16)


Disclosures: P. Vega-Fernandez: None; K. Rogers: None; A. Sproles: None; S. Thornton: None; L. Auld: None; J. Rodriguez-Smith: None; E. Ogbu: Cartesian Therapeutics, 2; K. Schmidt: None; M. Vater: None; K. Banschbach: None; G. Schulert: IpiNovoyx, 5, Novartis, 2, SOBI, 2; A. Grom: Novartis, 2, 5, Sobi, 2, 5, UpToDate, 9; S. Angeles-Han: None; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EMD Serono, 2, F. Hoffmann-La Roche, 2, Genentech, 5, GlaxoSmithKline, 2, Merck, 2, Novartis, 2, Pfizer, 2, 5, Sanofi, 2, UCB, 2; J. Huggins: None; D. Lovell: AbbVie, 2, Bristol-Myers Squibb(BMS), 2, Canadian Arthritis Society, 12, DSMB memberNIH-NIAMS and NIAID, Canadian Arthritis Society, Novartis, 2; A. Cassedy: None; Y. Baglaenko: None; T. Ting: None; S. Szabo: None.

To cite this abstract in AMA style:

Vega-Fernandez P, Rogers K, Sproles A, Thornton S, Auld L, Rodriguez-Smith J, Ogbu E, Schmidt K, Vater M, Banschbach K, Schulert G, Grom A, Angeles-Han S, Brunner H, Huggins J, Lovell D, Cassedy A, Baglaenko Y, Ting T, Szabo S. Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-disease-activity-in-the-knee-joint-through-clinical-radiologic-synovial-fluid-and-histopathologic-measurements-of-inflammation-in-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-disease-activity-in-the-knee-joint-through-clinical-radiologic-synovial-fluid-and-histopathologic-measurements-of-inflammation-in-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology